$Dare Bioscience(DARE.US)$Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced it was selected as a spoke for the Investor Catalyst Hub, a regional hub of ARPANET-H, a nationwide health innovation network launched by the Advanced Research Projects Agency for Health (ARPA-H). As an Investor Catalyst Hub spoke, Daré gains access to potential funding and flexible contracting for faster award execution compared to traditional government contracts. Spok...
Daré Bioscience Secures $22 Million in Strategic Financing to Propel Women's Health Innovations. Daré Bioscience, a leader in women's health innovation, has announced securing $22 million in non-dilutive strategic royalty financing. This infusion of capital is earmarked for the advancement of its Phase 3 first-in-category product candidates, setting a new pace in the realm of women's health care.$Dare Bioscience(DARE.US)$ https://stockregion.app/p/bioscience-company-secures-massive
$Dare Bioscience(DARE.US)$ NEWS Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women’s Health Product Candidates through Key Catalysts Daré Bioscience secured $22 million in non-dilutive strategic royalty financing to advance Phase 3 first-in-category women’s health product candidates through key catalysts. The transaction with XOMA provides significant capital for Daré to focus on advancing Ovaprene® and Sildenafil Cream, 3.6...
$Dare Bioscience(DARE.US)$Xoma Has Acquired An Economic Interest In Three Women's Health Assets From Daré Bioscience For An Upfront Payment Of $22M Benzinga· 1 min ago
$Dare Bioscience(DARE.US)$Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women’s Health Product Candidates Through Key Catalysts
Dare Bioscience股票討論區
Update
As an Investor Catalyst Hub spoke, Daré gains access to potential funding and flexible contracting for faster award execution compared to traditional government contracts. Spok...
Good news lately give a updated PT
Bioscience Company Secures Massive $22 Million Royalty Financing
Daré Bioscience, a leader in women's health innovation, has announced securing $22 million in non-dilutive strategic royalty financing. This infusion of capital is earmarked for the advancement of its Phase 3 first-in-category product candidates, setting a new pace in the realm of women's health care. $Dare Bioscience(DARE.US)$
https://stockregion.app/p/bioscience-company-secures-massive
Now just need volume!
NEWS
Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women’s Health Product Candidates through Key Catalysts
Daré Bioscience secured $22 million in non-dilutive strategic royalty financing to advance Phase 3 first-in-category women’s health product candidates through key catalysts. The transaction with XOMA provides significant capital for Daré to focus on advancing Ovaprene® and Sildenafil Cream, 3.6...
WooHoo 6 days later! Hehehe
Benzinga· 1 min ago
Hell yeah
暫無評論